Search trials – HealthDB

Активни:

Намерени 282 изпитвания Стр. 12 от 15

Active (not recruiting) Phase 2

A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis

Trial status: Authorised Proportion of participants who achieve clinical remission defined as 3‑component MMCS ≤2 (SFS ≤1, RBS = 0, and MES ≤1) at Week X, Proportion of participants who have a clinical response per 3 component MMCS (defined as a decrease from baseline of ≥2 points and ≥30%, and either a decrease in RBS of ≥1 point or an absolute RBS of 0 or 1) at Week X, Proportion of participants who achieve clinical remission per MMCS at Week X Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs of special interest and treatment discontinuations due to TEAEs, Changes in clinical laboratory parameters, electrocardiogram parameters, and vital signs, Change from baseline in 3-component modified Mayo Clinic Score (MMCS) (defined as sum of stool frequency subscore [SFS], rectal bleeding subscore [RBS], and Mayo endoscopic subscores [MES]a) at Week X

Начало: 25.06.2025 Възраст: от 18 г.

Austria, Belgium, Croatia +4 Odyssey Therapeutics Inc. 2024-520201-39-00

Active (not recruiting) Phase 3

C5751003 - AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER)

non-small cell lung cancer

Trial status: Authorised Confirmed ORR using RECIST v1.1 as assessed by BICR, PFS using RECIST v1.1 as assessed by investigator, Confirmed ORR using RECIST v1.1 as assessed by investigator, Duration of response (DOR) using RECIST v1.1 as assessed by BICR, DOR using RECIST v1.1 as assessed by investigator, Type, incidence, severity, seriousness, and relatedness of adverse events (AEs), Plasma concentration at end of infusion (CEOI) and Plasma predose concentration (Cpredose) for antibody conjugated monomethyl auristatin E (ac-MMAE) and unconjugated monomethyl auristatin E (MMAE), Incidence of antidrug antibodies (ADAs) OS, PFS using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) as assessed by BICR

Начало: 17.06.2025 Възраст: от 18 г.

Austria, Belgium, Bulgaria +12 Pfizer Inc. 2024-517968-36-00

Active (not recruiting) Phase 3

A multicentric, randomized, double-blind, parallel, placebo-controlled phase III study to assess the safety and efficacy of sovateltide in patients with acute cerebral ischemic stroke.

Acute cerebral ischemic stroke

Trial status: Authorised The proportion of acute cerebral ischemic stroke patients having a good functional outcome with NIHSS score of

Начало: 16.06.2025 Възраст: от 18 г.

Germany, Spain Pharmazz EU Limited 2024-519551-29-00

Active (not recruiting) Phase 2

A randomized phase II study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor-based endocrine therapy as first-line therapy of HR-positive and HER2-low/ultra-low advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling (The PONTIAC Study).

Unresectable locally recurrent or metastatic hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-low/ultralow breast cancer classified as non-luminal by gene expression profiling.

Trial status: Authorised OS, defined as the period from randomization date to death from any cause, as determined locally by the investigator (in all patients and HER2-low population)., ORR, defined as the rate of patients with complete response (CR) or partial response (PR), as determined locally by the investigator using RECIST v.1.1 (in all patients and HER2-low population)., CBR, defined as the rate of patients with objective response (CR or PR), or stable disease for at least 24 weeks, as determined locally by the investigator using RECIST v.1.1 (in all patients and HER2-low population)., DoR, defined as the period from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, as determined locally by the investigator using RECIST v.1.1 (in all patients and HER2-low population)., TTR, defined as the period from randomization date to the first objective tumor response (tumor shrinkage of ≥ 30%) observed for patients who achieved a CR or PR, as determined locally by the investigator using RECIST v.1.1 (in all patients and HER2-low population)., TTF, defined as the time from randomization date to discontinuation of treatment for any reason, including progressive disease, treatment toxicity, patient choice, and death., TFSC: time to first subsequent chemotherapy, defined as the time from randomization date to the beginning of the first subsequent chemotherapy after discontinuation of the trial regimen, Best percentage of change from baseline in the size of target tumor lesions, defined as the biggest decrease, or smallest increase if no decrease will be observed, as determined locally by the investigator using RECIST v.1.1., PFS2 is defined as the time from randomization date to the earliest progression event after that used for the primary variable PFS, or date of death as determined locally by the investigator using RECIST v.1.1., TFST, defined as the time from randomization to the earliest date of anti-cancer therapy start date following Study treatment discontinuation, or death., Changes from baseline in the EORTC QLQ-C30, EORTC QLQ-BR42 scales and the EQ-5D-5L index., Time to deteriorate in the EORTC QLQ-C30 and QLQ-BR42 subscales., Safety endpoints: Safety and tolerability as per NCI-CTCAE v.5.0., Exploratory endpoints can include (but are not limited to): Association of clinical outcomes, safety and/or tolerability profile with mutation profiling, copy number variability, gene expression, multiplex assays, proteomic analyses, digital pathology, immunohistochemistry, taxonomic or functional analyses performed on tissue and/or liquid biopsy samples., Exploratory endpoints can include (but are not limited to): Efficacy endpoints for all patients according to different clinicopathological characteristics and prior treatment for early breast cancer., Exploratory endpoints can include (but are not limited to): Association of treatment efficacy and/or safety outcomes in all patients with radiological imaging biomarkers. PFS, defined as the period from randomization date to the first occurrence of documented radiographic disease progression or death from any cause, whichever occurs first, as determined locally by the investigator using RECIST v.1.1. in HER2-low patients., PFS, defined as the period from randomization date to the first occurrence of documented radiographic disease progression or death from any cause, whichever occurs first, as determined locally by the investigator using RECIST v.1.1 in all patients.

Начало: 09.06.2025 Възраст: от 18 г.

Austria, Belgium, France +6 Medica Scientia Innovation Research S.L. 2024-512360-55-00

Active (not recruiting) Phase 3

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

Trial status: Authorised IGA score of 0 or 1 and a ≥2 grade improvement from baseline at Week 16., PASI 90 at Week 16.

Начало: 06.05.2025 Възраст: от 18 г.

Austria, Belgium, Denmark +5 Janssen Cilag International 2024-515706-77-00

Active (not recruiting) Phase 2

An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Sclerosis (PMS)

Non-active Progressive Multiple Sclerosis (PMS)

Trial status: Authorised Change from baseline for clinical measures of disability (includes EDSS, T25FW, 9HPT, SDMT)., YTB323 transgene expression levels by qPCR over time in blood; cellular kinetics parameters (Cmax, AUC, Tmax, Clast, Tlast)., Safety data from each dose level., Pre-existing and treatment-induced immunogenicity (humoral, anti-YTB323 antibody; and cellular, presence of CAR19 specific CD4 and CD8 T cells measuring interferon gamma production). Occurrence, severity and frequency of dose limiting toxicities (DLTs), Adverse Events (AEs) and change from baseline over 2 years in safety parameters including, but not limited to vital signs, laboratory, ECG, neurological status, and safety measures from brain and spinal cord MRIs.

Начало: 22.04.2025 Възраст: 18–64 г.

France, Germany, Italy +1 Novartis Pharma AG 2024-514006-31-00

Active (not recruiting) Phase 3

A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

relapsed or refractory mantle cell lymphoma (R/R MCL)

Trial status: Authorised Overall survival (OS), defined as the time from randomization to the date of death from any cause., Progression-free survival (PFS) as determined by investigator., Overall response rate (ORR) as determined by BIRC and by investigator per the Lugano 2014 criteria. ORR is defined as the proportion of patients who achieved a best overall response of partial response or complete response (CR)., Duration of response (DOR) as determined by BIRC and by investigator. It is defined as the time from the first qualifying response to the date of progression or death, whichever occurs first., Complete response rate (CRR), as determined by BIRC and by investigator. It is defined as the proportion of patients who achieved a best overall response of CR., Time to first response as determined by BIRC and by investigator. It is defined as time from randomization to first response., Time to initiation of new anticancer therapy., Patient-reported symptom burden and physical condition/fatigue as measured by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Non-Hodgkin Lymphoma High Grade Module 29 (EORTC-QLQ-NHL-HG29) questionnaire, and global health status (GHS) and physical function as measured by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)., Incidence and severity of treatment-emergent adverse events (TEAE)s graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 Progression-free survival (PFS), as assessed by blinded independent review committee (BIRC), defined as the time from randomization to the date of progression or death, whichever occurs first.

Начало: 21.04.2025 Възраст: от 18 г.

Austria, France, Germany +3 BeOne Medicines AG 2024-515593-27-00

Active (not recruiting) Phase 2

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa Lung 536)

Advanced or Metastatic Non-Squamous NSCLC

Trial status: Authorised Progression Free Survival (PFS): the time from the subject's randomization date to the first occurrence of radiographic progression per BICR based on RECIST v1.1 or death from any cause, whichever occurs earlier., Duration Of Response (DOR): the time from the first documented CR or PR per BICR to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause, whichever occurs first., Disease Control: best overall response of confirmed CR or confirmed PR, or SD for at least 11 weeks following randomization date based on RECIST v1.1, by the BICR. OR, PFS, DOR, and DC by investigator per RECIST v1.1., Overall Survival: the time from subject's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. Subjects with no documented death will be censored at the last known alive date., OR, PFS, OS, DOR, and DC in PD-L1 and c-Met subgroups. Part 1: dose-limiting toxicity., Part 2: efficacy endpoint is the OR as assessed by BICR (as confirmed CR or PR based on RECIST v1.1).

Начало: 07.04.2025 Възраст: от 18 г.

Belgium, France, Germany +4 AbbVie Deutschland GmbH & Co. KG 2024-514465-18-00

Active (not recruiting) Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)

myelodysplastic neoplasms/syndromes (MDS)

Trial status: Authorised 1. Proportion of participants achieving TI for ≥ 24 weeks from baseline through week 48, 2. Proportion of participants with HTB achieving TI for ≥ 8 weeks from baseline through week 24, 3. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), 4. Change from baseline in clinical laboratory values, vital signs, and electrocardiograms (ECGs) Proportion of participants achieving transfusion independence (TI) for ≥ 8 weeks from baseline through week 24

Начало: 28.03.2025 Възраст: от 18 г.

Bulgaria, Czech Republic, France +8 Takeda Development Center Americas Inc. 2024-516009-22-00

Active (not recruiting) Phase 3

A Global Multicenter, Open Label, Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination with Acalabrutinib versus Immunochemotherapy in Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA-2 Study)

Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial status: Authorised Key secondary endpoint: Investigator-assessed PFS: The time from randomization to PD or death from any cause, whichever occurs first., Other secondary endpoints: OS: The time from randomization to death., IRC- and investigator-assessed ORR: ORR includes complete response (CR), complete response with incomplete bone marrow recovery (CRi) or partial response (PR). CLL responsewill be assessed according to IWCLL NCI-WG guidelines (2018 Edition), and SLL response will be assessed according to Lugano 2014 criteria for response assessment in lymphoma., IRC- and investigator-assessed TTR: The interval from randomization to the date of the first confirmed CR, CRi, or PR., IRC- and investigator-assessed DOR: The interval from the date of first confirmed CR, CRi or PR to PD, or the start of a new anti-tumor treatment, or death, whichever occurs first., MRD negativity rate: Proportion of patients with MRD-negative result in bone marrow, peripheral blood, either or both., Safety and tolerability of patients: Treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) will be evaluated., Concentration data of Lisaftoclax and critical parameters of population pharmacokinetics. IRC-assessed PFS: The time from randomization to PD or death from any cause, whichever occurs first.

Начало: 18.02.2025 Възраст: от 18 г.

Bulgaria, Czech Republic, Spain Ascentage Pharma Group Inc. 2024-514084-26-00

Active (not recruiting) Phase 1

Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)

Immune-mediated necrotizing myopathy Antiphospholipid syndrome Behçet’s Syndrome Bullous pemphigoid +2

Trial status: Authorised

Начало: 11.02.2025 Възраст: от 18 г.

Austria, Bulgaria, Croatia +11 Chugai Pharmaceutical Co. Ltd. 2024-511346-39-00

Active (not recruiting) Phase 3

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus of Lichen Simplex Chronicus (LSC) in adults

Neurodermatitis

Trial status: Authorised Absolute change in weekly average of daily WI-NRS from baseline to Week 24, Absolute change in weekly average of daily Itch-related Sleep Disturbance NRS from baseline to Week 24, Absolute change in ItchyQoL score from baseline to Week 24, Absolute change in DLQI total score from baseline to Week 24, Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 12, Incidence of treatment-emergent ADA against dupilumab, Percentage of participants experiencing TEAEs or SAEs from baseline through Week 24, Percentage change in weekly average of daily WI-NRS from baseline to Week 24, Percentage change in weekly average of daily Itch-related Sleep Disturbance NRS from baseline to Week 24, Proportion of participants with IGA 0 or 1 score for LSC at Week 12 and Week 24, Proportion of participants with both an improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 24 and an IGA 0 or 1 score for LSC at Week 24 Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 24

Начало: 04.02.2025 Възраст: от 18 г.

Belgium, Czech Republic, Germany +5 Sanofi-Aventis Recherche & Developpement 2024-514737-37-00

Active (not recruiting) Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Pancreatic Ductal Adeno Carcinoma Colorectal Cancer Non- Small Cell Lung Cancer (NSCLC) Renal Cell Carcinoma

Trial status: Authorised

Начало: 30.01.2025 Възраст: от 18 г.

France, Germany, Italy +1 Kura Oncology Inc. 2024-513285-19-00

Active (not recruiting) Phase 2

GEMOXIA02: HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY

NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA

Trial status: Authorised Safety :NCI-CTCAE, Quality of life (QLQ-C30 questionnaire). The time to a final deterioration in the global health score (decrease of 5 points or more with no further improvement before death). The delay will be calculated from date of the first cycle to QoL evaluation or date of death or date of last news if the patient has no deterioration, Secondary resectability rate (as evaluated by an experienced hepatic surgeon), Overall survival (estimated by the time between the date of inclusion and the date of death or date of last news for alive patients), Progression-free survival by CT-scan/MRI according to the investigator's opinion (defined as the time between the date of inclusion and the date of first progression or death [whichever occurs first] or date of last news for patients alive without any progression) The primary endpoint is the percentage of patients with an objective response (defined as partial or complete response) 4 months after inclusion (using RECIST v1.1 criteria)

Начало: 29.01.2025 Възраст: от 18 г.

France Centre Hospitalier Universitaire De Montpellier 2024-519132-17-00

Active (not recruiting) Phase 3

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Primary Immune thrombocytopenia (ITP)

Trial status: Authorised Proportion of participants achieving platelet counts of at least 50 × 10^9/L for at least 4 of the 6 study visits between study weeks 19 and 24 of the DBTP, Proportion of participants achieving platelet counts of at least 50 × 10^9/L for at least 6 of the 8 study visits between study weeks 17 and 24 of the DBTP, Proportion of participants achieving platelet counts of at least 50 × 10^9/L for at least 8 of the 12 study visits between weeks 13 and 24 of the DBTP, Proportion of participants achieving a platelet count of at least 50 × 10^9/L on at least 4 occasions at any time until study week 12 during the DBTP, Time to response, defined as the time to achieve 2 consecutive platelet counts of at least 50 × 10^9/L at any time during the DBTP, Proportion of participants with an International Working Group (IWG) response during the DBTP, Proportion of participants with International Working Group (IWG) complete response during the DBTP, Proportion of participants with initial response, defined as a platelet count of at least 30 × 10^9/L and a 2-fold increase from baseline in platelet count at study week 5 of the DBTP, Time to achieve a platelet count of at least 30 × 10^9/L and a 2-fold increase from baseline in platelet count during the DBTP, Number of cumulative weeks during the DBTP with platelet counts of at least 30 × 10^9/L and ≥20 × 10^9/L above baseline, Number of cumulative weeks during the DBTP with platelet counts of at least 30 × 10^9/L and at least 20 × 10^9/L above baseline in participants with baseline platelet counts of

Начало: 24.01.2025 Възраст: от 18 г.

Austria, Bulgaria, Croatia +11 Argenx 2024-515451-38-00

Active (not recruiting) Phase 2

A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations

Advanced or metastatic untreated EGFR mutation positive NSCLC

Trial status: Authorised • OS in patients treated with osimertinib first followed by dacomitinib and in patients treated with dacomitinib first followed by osimertinib • PFS at the time of study second-line therapy failure (PFS2) in patients treated with front-line osimertinib or dacomitinib; • PFS in patients treated with osimertinib first or dacomitinib first; • Response Rate (RR) with dacomitinib or osimertinib; • RR, PFS and OS with osimertinib followed by dacomitinib or with the opposite sequence in patients with u OS in patients treated with osimertinib first or dacomitinib first

Начало: 21.01.2025 Възраст: от 18 г.

Italy, Spain Fondazione Ricerca Traslazionale 2024-518223-29-00

Active (not recruiting) Phase 2

PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older

colon cancer

Trial status: Authorised The dose intensity, The overall tolerance to the treatments, The time to recurrence, Overall survival, The time to decrease in autonomy, The time to decrease in the quality of life The primary endpoint is relapse-free survival (RFS). It is defined as the time limit between the randomisation date and the date of the first recurrence (local or remote) or the date of death, regardless of the cause. All second cancers, colon or not, shall not be taken into account. The living patients without recurrence shall be censored at the date of their last assessment.

Начало: 17.01.2025 Възраст: от 65 г.

Belgium, France Fondation Franc.Cancerologie Digestive 2024-518741-21-00

Active (not recruiting) Phase 4

Impact of Inhaled BGF 160 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient

Impact of inhaled BGF 160 on complexity and variability of tidal breathing and oscillatory mechanics in stable COPD patient

Trial status: Authorised Change between V2 base (pre-treatment) and V3 peak (2 hours (+/-30min) post dose) of : - Impulse oscillometry or forced oscillation: resistances at 5Hz, reactance at 5Hz - Spirometry: Changes in FEV1 - Plethysmographic Functional residual capacity (FRC), Changes between V2 base measurement (pre-treatment) and V3 peak (2 hours (+/-30min) measurement for noise limit, respiratory frequency, volume, largest Lyapounov component, resistances at 5Hz, reactance at 5Hz, FEV1and FRC versus TDI at V3 (in term of continuous variable and in term of binary variable “responder/non responder”; a response is defined by a change in TDI ≥ +1 between baseline and V3), Dyspnea and symptom scores: - Baseline dyspnea index ( BDI) - Transition dyspnea index (TDI) - Modified dyspnea profile ( MDP) - CAT score - Likert scale for dyspnea and general health, Noise limit, respiratory frequency, volume, largest Lyapounov component, resistances at 5Hz, reactance at 5Hz, FEV1, FRC, and VAS dyspnea/chest tightness Multiple primary endpoints characterizing the change in ventilation pattern complexity and variability between V2 baseline (pre-treatment) and V3 peak (2 hours (+/-30min) post dose at one month) : noise limit, respiratory frequency, volume and largest Lyapounov component (an indicator of the sensitivity of the system to initial condition.

Начало: 16.12.2024 Възраст: от 18 г.

France Centre Hospitalier Universitaire De Lille 2024-514097-52-00

Active (not recruiting) Phase 3

Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Trial status: Authorised Adverse outcome of death or adjudicated severe bleeding in utero, and up to the first week post birth, or platelet count at birth

Начало: 10.12.2024 Възраст: 18–64 г.

Austria, Germany, Netherlands +1 Janssen Cilag International 2023-509434-19-00

Active (not recruiting) Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

Prurigo Nodularis

Trial status: Authorised Proportion of participants achieving Itch NRS4 at Week 24, Proportion of participants achieving IGA CPG S-TS at Week 24, Proportion of participants achieving Itch NRS4 at Week 4 Proportion of participants achieving Itch NRS4 (≥ 4-point improvement [reduction] in Itch NRS score from baseline) and IGA-CPG-S-TS (IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline) at Week 24

Начало: 27.11.2024 Възраст: от 18 г.

Austria, Bulgaria, France +4 Incyte Corp. 2024-511879-16-00

1 … 10 11 12 13 14 15